Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4+ T cell responses

Clinical and Experimental Allergy

Volumn 41, Issue 2, 2011, Pages 192-203

  Wambre, E ^a   Bonvalet, M ^a   Bodo, V B ^a   Maillere B ^b   Leclert, G ^a   Moussu, H ^a   Von Hofe, E ^c   Louise, A ^d   Balazuc, A M ^d   Ebo, D ^e   Hoarau, C ^f   Garcia, G ^g   Van Overtvelt, L ^a   Moingeon, P ^a  

^a Stallergenes SA   (France)

^b DIF   (France)

^c Antigen Express Inc   (United States)

^d INSTITUT PASTEUR   (France)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f UNIVERSITY HOSPITAL OF TOURS   (France)

^g HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Allergens; Immunotherapy; MHC class II tetramers; T cell polarization; Tolerance

Indexed keywords

ALLERGEN; GAMMA INTERFERON; HOUSE DUST ALLERGEN; INTERLEUKIN 10;

ALLERGIC RHINITIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BARE LYMPHOCYTE SYNDROME; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CYTOFLUOROMETRY; GENE EXPRESSION; HOUSE DUST ALLERGY; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMORY CELL; POLLEN ALLERGY; PRIORITY JOURNAL; TH1 CELL; TH17 CELL; TH2 CELL;

ANTIGENS, DERMATOPHAGOIDES; ANTIGENS, PLANT; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; SEASONS;

EID: 78651415619     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2010.03641.x     Document Type: Article

References (48)

1. Ebner C, Siemann U, Bohle B et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997; 27:1007-5.
2. + T cells in primary culture: relationship to expression of allergic disease. J Allergy Clin Immunol 1997; 99:563-9.
3. Akdis CA, Blaser K. Mechanisms of allergen-specific immunotherapy. Allergy 2000; 55:522-30.
4. Robinson DS, Larche M, Durham SR. T regs and allergic disease. J Clin Invest 2004; 114:1389-97.
5. El Biaze M, Boniface S, Koscher V et al. T cell activation, from atopy to asthma: more a paradox than a paradigm. Allergy 2003; 58:844-53.
6. Macaubas C, Wahlstrom J, Galvao da Silva AP et al. Allergen-specific MHC-class II tetramer+cells are detectable in allergic, but not in non allergic, individuals. J Immunol 2006; 176:5069-77.
7. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998; 102:157-64.
8. Till S. Immunotherapy: readdressing the balance between TH2 and TH1 cells. Clin Exp Allergy 1997; 27:981-5.
9. Mavroleon G. Restoration of cytokine imbalance by immunotherapy. Clin Exp Allergy 1998; 28:943-9.
10. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61:151-65.
11. Ebner C, Schenk S, Najafian N et al. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients. J Immunol 1995; 154:1932-40.
12. Akdis M, Verhagen J, Taylor A et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199:1567-75.
13. + T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers. J Immunol 2008; 180:4514-22.
14. Jahn-Schmid B, Radakovics A, Luttkopf D et al. Bet v 1 142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens. J Allergy Clin Immunol 2005; 116:213-9.
15. Bateman EA, Ardern-Jones MR, Ogg GS. Identification of an immunodominant region of Fel d 1 and characterization of constituent epitopes. Clin Exp Allergy 2008; 38:1760-8.
16. + T cells. J Allergy Clin Immunol 2006; 118:1350-6.
17. Wambre E, Van Overtvelt L, Maillère B et al. Single cell assessment of allergen-specific T cell responses with MHC-class II peptide tetramers: methodological aspects. Int Arch Allergy Immunol 2008; 146:99-112.
18. Altman JD, Moss PA, Goulder PJ et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274:94-6.
19. Danke NA, Kwok WW. HLA class II-restricted CD4+T cell responses directed against influenza viral antigens postinfluenza vaccination. J Immunol 2003; 171:3163-9.
20. McMichael AJ, Kelleher A. The arrival of HLA class II tetramers. J Clin Invest 1999; 104:1669-70.
21. Ardern-Jones MR, Black AP, Bateman EA, Ogg GS. Bacterial superantigen facilitates epithelial presentation of allergen to T helper 2 cells. Proc Natl Acad Sci USA 2007; 104:5557-62.
22. Kinnunen T, Jutila K, Kwok WW et al. Potential of an altered peptide ligand of lipocalin allergen Bos d 2 for peptide immunotherapy. J Allergy Clin Immunol 2007; 119:965-72.
23. John-Schmidt B, Sirven P, Leb V et al. Characterization of HLA class II/peptide TCR interactions of the immunodominant T cell epitope in Art v 1, the major Artemisia pollen allergen. J Immunol 2008; 181:3636-42.
24. Texier C, Pouvelle S, Busson M et al. HLA-DR restricted peptide candidates for bee venom immunotherapy. J Immunol 2000; 164:3177-84.
25. Castelli FA, Buhot C, Sanson A et al. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol 2002; 169:6928-34.
26. Kallinteris NL, Lu X, Blackwell CE, Von Hofe E, Humphreys RE, Xu M. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. Expert Opin Biol Ther 2006; 6:1311-21.
27. Fourneau JM, Cohen H, van Endert PM. A chaperone-assisted high yield system for the production of HLA-DR4 tetramers in insect cells. J Immunol Methods 2004; 285:253-64.
28. Samoilava EB, Horton JL, Zhang H, Khoury SJ, Weiner HL, Chen Y. CTLA-4 is required for the induction of high dose oral tolerance. Int Immunol 1998; 10:491-8.
29. Campbell JD, Gangur V, Simons FE, HayGlass KT. Allergic humans are hyporesponsive to a CXCR3 ligand-mediated Th1 immunity-promoting loop. FASEB J 2004; 18:329-31.
30. Ardern-Jones MR, Black AP, Bateman EA, Og GS. Bacterial superantigen facilitates epithelial presentation of allergen to T helper 2 cells. Proc Natl Acad Sci USA 2007; 104:5557-62.
31. Higgins JA, Thorpe CJ, Hayball JD, O'Hehir RE, Lamb JR. Overlapping T-cell epitopes in the group I allergen of Dermatophagoides species restricted by HLA-DP and HLA-DR class II molecules. J Allergy Clin Immunol 1994; 93:891-9.
32. + T cell clones. J Immunol 1992; 148:738-45.
33. Hales BJ, Thomas WR. T-cell sensitization to epitopes from the house dust mites Dermatophagoides pteronyssinus and Euroglyphus maynei. Clin Exp Allergy 1997; 27:868-75.
34. Joost van Neerven R, van t'Hof W, Ringrose JH et al. T cell epitopes of house dust mite major allergen Der p 2. J Immunol 1993; 151:2326-35.
35. O'Hehir RE, Verhoef A, Panagiotopoulou E et al. Analysis of human T cell responses to the group II allergen of Dermatophagoides species: localization of major antigenic sites. J Allergy Clin Immunol 1993; 92:105-13.
36. Verhoef A, Higgins JA, Thorpe CJ et al. Clonal analysis of the atopic immune response to the group 2 allergen of Dermatophagoides spp. identification of HLA-DR and DQ restricted T cell epitopes. Int Immunol 1993; 5:1589-97.
37. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005; 17:326-32.
38. Kalia V, Sarkar S, Ahmed R. Fine-tuning CD4+ central memory T cell heterogeneity by strength of stimulation. Eur J Immunol 2008; 38:15-9.
39. + T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol 2008; 152:522-31.
40. Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 2005; 174:1037-45.
41. Thomas WR, Hales BJ. T and B cell responses to HDM allergens and antigens. Immunol Res 2007; 37:187-99.
42. Gardner LM, Spyroglou L, O'Hehir RE, Rolland JM. Increased allergen concentration enhances IFNγ production by allergic donor T cells expressing a peripheral tissue trafficking phenotype. Allergy 2004; 59:1308-17.
43. Wierenga EA, Snoek M, Henk M et al. Human allergen-specific types 1 and 2 T helper cell clones. J Immunol 1991; 147:2942-9.
44. Parronchi P, Macchia D, Piccinni MP et al. Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. Proc Natl Acad Sci USA 1991; 88:4538-42.
45. Chapman MD, Wünschmann S, Pomés A. Protease as Th2 adjuvants. Curr Allergy Asthma Rep 2007; 7:363-7.
46. Trivedi B, Valerio C, Slater JE. Endotoxin content of standardized allergen vaccines. J Allergy Clin Immunol 2003; 111:777-83.
47. Barret NA, Maekawa A, Rahman OM, Austen KF, Kanaoka Y. Dectin-2 recognition of house dust mite triggers cysteinyl leukotriene generation by dendritic cells. J Immunol 2009; 182:1119-28.
48. Zhang N, Van Zele T, Perez-Novo C et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol 2008; 122:961-8.